Mint Pharmaceuticals Inc. is recalling all lots of its prescription losartan tablets, in 50 mg and 100 mg strengths, after tests found an azido impurity -2-butyl-4-chloro-1H imidazol-1-yl)methyl)-[1,1'-biphenyl]-2-yl)-1H tetrazole) above the acceptable limit.
OTTAWA, ON, Oct. 26, 2021 /CNW/ - Mint Pharmaceuticals Inc. is recalling all lots of its prescription losartan tablets, in 50 mg and 100 mg strengths, after tests found an azido impurity (5-(4'-((5-(azidomethyl)-2-butyl-4-chloro-1H imidazol-1-yl)methyl)-[1,1'-biphenyl]-2-yl)-1H tetrazole) above the acceptable limit. Long-term exposure to the impurity at levels above what is considered safe could potentially increase the risk of cancer.
Please see the full advisory for more information, including what Canadians should do and Health Canada's work to address the issue of azido impurities found in certain drugs.
|
Product |
Company |
DIN |
Lot |
Expiry |
|
MINT-LOSARTAN/HCTZ 50/12.5 mg TABLETS |
Mint Pharmaceuticals Inc. |
02389657 |
2005006959 |
April 2023 |
|
MINT-LOSARTAN/HCTZ 50/12.5 mg TABLETS |
Mint Pharmaceuticals Inc. |
02389657 |
2005006960 |
April 2023 |
|
MINT-LOSARTAN/HCTZ 50/12.5 mg TABLETS |
Mint Pharmaceuticals Inc. |
02389657 |
2005006961 |
April 2023 |
|
MINT-LOSARTAN/HCTZ 50/12.5 mg TABLETS |
Mint Pharmaceuticals Inc. |
02389657 |
2005006962 |
April 2023 |
|
MINT-LOSARTAN/HCTZ 50/12.5 mg TABLETS |
Mint Pharmaceuticals Inc. |
02389657 |
2005006963 |
April 2023 |
|
MINT-LOSARTAN/HCTZ 50/12.5 mg TABLETS |
Mint Pharmaceuticals Inc. |
02389657 |
2005011154 |
June 2023 |
|
MINT-LOSARTAN/HCTZ 50/12.5 mg TABLETS |
Mint Pharmaceuticals Inc. |
02389657 |
2005011156 |
June 2023 |
|
MINT-LOSARTAN/HCTZ 100/12.5 mg TABLETS |
Mint Pharmaceuticals Inc. |
02389665 |
2005006807 |
April 2022 |
|
MINT-LOSARTAN/HCTZ 100/12.5 mg TABLETS |
Mint Pharmaceuticals Inc. |
02389665 |
2005006808 |
April 2022 |
|
MINT-LOSARTAN/HCTZ 100/12.5 mg TABLETS |
Mint Pharmaceuticals Inc. |
02389665 |
2005006809 |
April 2022 |
|
MINT-LOSARTAN/HCTZ 100/12.5 mg TABLETS |
Mint Pharmaceuticals Inc. |
02389665 |
2005006810 |
April 2022 |
|
MINT-LOSARTAN/HCTZ 100/12.5 mg TABLETS |
Mint Pharmaceuticals Inc. |
02389665 |
2105002149 |
December 2022 |
|
MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETS |
Mint Pharmaceuticals Inc. |
02389673 |
1805012687 |
October 2021 |
|
MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETS |
Mint Pharmaceuticals Inc. |
02389673 |
1805012688 |
October 2021 |
|
MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETS |
Mint Pharmaceuticals Inc. |
02389673 |
1805012689 |
October 2021 |
|
MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETS |
Mint Pharmaceuticals Inc. |
02389673 |
1805012792 |
October 2021 |
|
MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETS |
Mint Pharmaceuticals Inc. |
02389673 |
1905001010 |
December 2021 |
|
MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETS |
Mint Pharmaceuticals Inc. |
02389673 |
1905001011 |
December 2021 |
|
MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETS |
Mint Pharmaceuticals Inc. |
02389673 |
2005006947 |
April 2023 |
|
MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETS |
Mint Pharmaceuticals Inc. |
02389673 |
2005006949 |
April 2023 |
|
MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETS |
Mint Pharmaceuticals Inc. |
02389673 |
2005006950 |
April 2023 |
|
MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETS |
Mint Pharmaceuticals Inc. |
02389673 |
2005006951 |
April 2023 |
|
MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETS |
Mint Pharmaceuticals Inc. |
02389673 |
2005007297 |
April 2023 |
|
MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETS |
Mint Pharmaceuticals Inc. |
02389673 |
2005007298 |
April 2023 |
|
MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETS |
Mint Pharmaceuticals Inc. |
02389673 |
2005013776 |
August 2023 |
|
MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETS |
Mint Pharmaceuticals Inc. |
02389673 |
2105002150 |
December 2023 |
Également disponible en français
SOURCE Health Canada
